Kisho

Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy

Back to Adult Lymphoma

Adult Lymphoma — NIH Grants & Funding

Active and recent NIH-funded research on Adult Lymphoma. Data from NIH RePORTER, last 36 months.

MONDO:0003660

NIH-funded research on Adult Lymphoma

active grants

institutions

researchers

new in last 12 mo.

$74.8M in NIH funding over the last 36 months. Data from NIH RePORTER.

I'm looking for:

Or filter by research focus

Only show active grants

Basic Science(12)

Basic ScienceR01Active

Essential role of the cyclin-G associated kinase (GAK) in diffuse large B-cell lymphoma progression

Al Ali, Hassan et al.·UNIVERSITY OF MIAMI SCHOOL OF MEDICINE·CORAL GABLES, FL

$2,617,975 (FY2025)

Adult Lymphoma — NIH Grants & Funding

Basic Science(12)

Essential role of the cyclin-G associated kinase (GAK) in diffuse large B-cell lymphoma progression

Epigenetic basis and therapeutic targeting of the unique lymphoma immunological niche

The role of Galpha13 signaling in suppression of lymphoma

Molecular diagnosis and outcome prediction in lymphoma

Oncogenic mechanisms and molecular targets in lymphoma

Impeding HIV-1-associated Non-Hodgkin's Lymphoma development by antagonizing Vpr

Single-cell Analysis of Primary Effusion Lymphoma Patient-Derived Xenografts from HIV-AIDS Patients to Identify Molecular Targets for Intervention

(PQ5) Contribution of mitochondrial pathways to metabolic heterogeneity in molecular subtypes of Diffuse Large B Cell Lymphoma

Role of FBXO45 in Diffuse Large B Cell Lymphoma Pathogenesis

Role of KMT2D Gene Inactivation in B cell Non Hodgkin Lymphoma

Translational(12)

The role of CEACAM1 in oncogenic B-cell receptor signaling and immunotherapy in mantle cell lymphoma

Inhibition of T-cell Receptor Signaling for Treatment of Adult T-cell Leukemia Lymphoma

Targeting EGR1 signaling pathways in diffuse large B cell lymphoma

CCR4-IL2 Bispecific Immunotoxin for Targeted Therapy of Cutaneous T-Cell Lymphoma

Mechanism-Based Targeting of Mantle Cell Lymphoma

A Genomic Framework for Molecular Risk Prediction & Individualized Lymphoma Therapy

Targeting SOX11 in Mantle Cell Lymphoma

Functional characterization and rational therapeutic targeting of 18q DNA copy number gains in diffuse large B-cell lymphoma

AVM0703 combined with Non-Hodgkin's Lymphoma standard of care to enhance complete response rates without additional toxicities

Development of first-in-class histone acetyltransferase (HAT) activators for precision targeting of epigenetic derangements in lymphoma

Clinical(12)

Clinical development of mechanism-based lymphoma therapies

Evaluation of an implantable microdevice for rapid cancer drug screening directly in T cell lymphoma patients

A Phase 2 multi-center trial of CD5 CAR T-cell therapy in patients with T-cell lymphoma

From pathogenesis to new therapeutic targets in diffuse large B cell lymphoma

Targeted treatment of B-cell Lymphoma

Targeting Tumor-Associated Macrophages to Treat Lymphoma

Assay Development and Prognostic Model for Predicting Early Clinical Failure in Follicular Lymphoma

Translation of a novel combination therapy approach for non-Hodgkin lymphoma

Expedited Expansion Cohort Clinical Trial for Relapsed/Refractory 'no-option' Non-Hodgkin's Lymphoma/Leukemia Patients

THE T-CELL RECEPTOR'S ROLE IN T-CELL LYMPHOMA PATHOGENESIS

Epi / Nat. History(2)

Functional state of CD8+ T cell immunity in adult T-cell leukemia/lymphoma

Defining the genomic and microenvironmental features of diffuse large B cell lymphoma in HIV + patients (Biospecimens/Biocohort)

Gene/Cell Therapy(3)

CD5-deleted chimeric antigen receptor cells (Senza5 CART5) to enhance immunotherapy against T cell non-Hodgkin lymphoma (NHL): a first-in-human phase I clinical trial

Immunomodulatory AVM0703 to bridge Relapsed/Refractory Diffuse Large B-Cell Lymphoma patients to CAR-T cell immunotherapy

A Phase 1 Study of Patient-Derived Multi-Tumor-Associated Antigen Specific T Cells (MT-601) Administered to Patients with Relapsed Non-Hodgkin Lymphoma

Other(5)

New Therapeutic Vulnerabilities for Aggressive B-Cell Lymphoma

Targeting transducin Beta-like protein 1 in mantle cell lymphoma

Precision Approaches to Treat Mantle Cell Lymphoma: Integrating Multi-omics Based Models

Overcoming Drug Resistance Driven by BCL10 Mutations in Diffuse Large B Cell Lymphoma

Role of ubiquitin ligases in mantle cell lymphoma